MA33407B1 - Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii - Google Patents

Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii

Info

Publication number
MA33407B1
MA33407B1 MA34461A MA34461A MA33407B1 MA 33407 B1 MA33407 B1 MA 33407B1 MA 34461 A MA34461 A MA 34461A MA 34461 A MA34461 A MA 34461A MA 33407 B1 MA33407 B1 MA 33407B1
Authority
MA
Morocco
Prior art keywords
kat
bicyclic
inhibitors
tricyclic compounds
compounds
Prior art date
Application number
MA34461A
Other languages
English (en)
Inventor
Michelle Marie Claffey
Amy Beth Dounay
Xinmin Gan
Matthew Merrill Hayward
Suobao Rong
Jamison Bryce Tuttle
Patrick Robert Verhoest
Original Assignee
Pfizer
Cabinet Patentmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Cabinet Patentmark filed Critical Pfizer
Publication of MA33407B1 publication Critical patent/MA33407B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE X : (X), DANS LAQUELLE A, X, Y, Z, R5, R6A ET R6B SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, AINSI QUE DES SELS PHARMACEUTIQUEMENT ACCEPTABLES, UTILES DANS LE TRAITEMENT DES DÉFICITS COGNITIFS LIÉS À LA SCHIZOPHRÉNIE ET D'AUTRES TROUBLES NEURODÉGÉNÉRATIFS ET/OU NEUROLOGIQUES CHEZ DES MAMMIFÈRES, NOTAMMENT DES HUMAINS.
MA34461A 2009-06-18 2010-05-26 Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii MA33407B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21814909P 2009-06-18 2009-06-18
US33438910P 2010-05-13 2010-05-13
PCT/IB2010/052349 WO2010146488A1 (fr) 2009-06-18 2010-05-26 Composes bicycliques et tricycliques utilises en tant qu'inhibiteurs de kat ii

Publications (1)

Publication Number Publication Date
MA33407B1 true MA33407B1 (fr) 2012-07-03

Family

ID=42732684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34461A MA33407B1 (fr) 2009-06-18 2010-05-26 Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii

Country Status (27)

Country Link
US (1) US8183238B2 (fr)
EP (1) EP2443092B1 (fr)
JP (1) JP5643818B2 (fr)
KR (1) KR101390023B1 (fr)
CN (1) CN102482221B (fr)
AP (1) AP2012006071A0 (fr)
AR (1) AR077147A1 (fr)
AU (1) AU2010261399B2 (fr)
BR (1) BRPI1011784A2 (fr)
CA (1) CA2763960C (fr)
CO (1) CO6470895A2 (fr)
CR (1) CR20110625A (fr)
CU (1) CU20110234A7 (fr)
DK (1) DK2443092T3 (fr)
DO (1) DOP2011000381A (fr)
EA (1) EA201190287A1 (fr)
EC (1) ECSP11011539A (fr)
ES (1) ES2538386T3 (fr)
IL (1) IL216603A (fr)
MA (1) MA33407B1 (fr)
MX (1) MX2011013870A (fr)
PE (1) PE20120432A1 (fr)
SG (1) SG176288A1 (fr)
TW (1) TW201100082A (fr)
UY (1) UY32712A (fr)
WO (1) WO2010146488A1 (fr)
ZA (1) ZA201108964B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011336214B2 (en) * 2010-12-01 2015-08-20 Pfizer Inc. KAT II inhibitors
MX2013005915A (es) * 2010-12-01 2013-07-03 Pfizer Inhibidores de kat ii.
KR101952981B1 (ko) * 2011-07-07 2019-02-27 구미아이 가가쿠 고교 가부시키가이샤 니트로벤젠 화합물의 제조방법
JP2015523352A (ja) * 2012-06-15 2015-08-13 ファイザー・インク Ｋａｔｉｉ阻害剤としての三環式化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
DK2746250T3 (en) * 2012-12-21 2018-01-02 Abx Advanced Biochemical Compounds Gmbh Intermediates and Processes for Preparation of 18F-Labeled Amino Acids
WO2014174745A1 (fr) * 2013-04-26 2014-10-30 国立大学法人京都大学 INHIBITEUR D'Eg5
JP6442485B2 (ja) * 2014-04-23 2018-12-19 田辺三菱製薬株式会社 新規二環性または三環性複素環化合物
CN104592333B (zh) * 2014-07-23 2017-06-27 江西科技师范大学 一种合成5‑羧基‑2’‑脱氧胞苷的方法
US10793582B2 (en) 2015-10-22 2020-10-06 Mitsubishi Tanabe Pharma Corporation Bicyclic heterocyclic compound
GB201613163D0 (en) * 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018155260A1 (fr) * 2017-02-23 2018-08-30 株式会社Ihi Sonde de détection de radicaux oh, dispositif de mesure de radicaux oh et procédé de mesure de radicaux oh
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
CN115872970A (zh) * 2022-12-08 2023-03-31 青岛普力机电工程有限公司 一种从乳酸原料到高纯丙交酯连续生产的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0881443A (ja) * 1994-09-12 1996-03-26 Otsuka Pharmaceut Co Ltd 細胞外マトリックス金属プロテアーゼ阻害剤
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
EP1002535A1 (fr) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou Nouvelle utilisation des antagonistes du glutamate pour le traitement du cancer
EP1644335A4 (fr) * 2003-07-11 2008-06-04 Bristol Myers Squibb Co Derives de tetrahydroquinoleine constituant des modulateurs des recepteurs des cannabinoides
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
EP2222662A4 (fr) * 2007-11-15 2011-08-03 Univ Maryland Inhibiteurs de la kynurénine-aminotransférase

Also Published As

Publication number Publication date
CA2763960C (fr) 2014-07-08
MX2011013870A (es) 2012-02-01
DOP2011000381A (es) 2012-02-29
CO6470895A2 (es) 2012-06-29
CR20110625A (es) 2012-02-24
US20100324043A1 (en) 2010-12-23
ES2538386T3 (es) 2015-06-19
AR077147A1 (es) 2011-08-03
AU2010261399B2 (en) 2014-07-17
AU2010261399A1 (en) 2012-01-12
UY32712A (es) 2011-01-31
AP2012006071A0 (en) 2012-02-29
US8183238B2 (en) 2012-05-22
CN102482221A (zh) 2012-05-30
EP2443092B1 (fr) 2015-04-08
CU20110234A7 (es) 2012-06-21
CN102482221B (zh) 2014-10-22
CA2763960A1 (fr) 2010-12-23
KR20120027480A (ko) 2012-03-21
ZA201108964B (en) 2012-08-29
JP5643818B2 (ja) 2014-12-17
EP2443092A1 (fr) 2012-04-25
SG176288A1 (en) 2012-01-30
PE20120432A1 (es) 2012-05-05
EA201190287A1 (ru) 2012-06-29
ECSP11011539A (es) 2012-01-31
IL216603A0 (en) 2012-02-29
JP2012530129A (ja) 2012-11-29
DK2443092T3 (en) 2015-04-27
IL216603A (en) 2015-07-30
HK1166980A1 (en) 2012-11-16
KR101390023B1 (ko) 2014-04-29
BRPI1011784A2 (pt) 2016-03-22
TW201100082A (en) 2011-01-01
WO2010146488A1 (fr) 2010-12-23

Similar Documents

Publication Publication Date Title
MA33407B1 (fr) Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii
EP2400847A4 (fr) Composés spécifiques de type diarylhydantoïne et diarylthiohydantoïne
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
MA35285B1 (fr) Indazoles
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
PH12013501556A1 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
MA31373B1 (fr) Composes amino-heterocycliques
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
EP2091955A4 (fr) Composés d'alcoxy pour le traitement de maladies
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
TW200734311A (en) New compounds
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
MA35286B1 (fr) Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
WO2009067493A3 (fr) Benzènes 1,3,5-trisubstitués pour le traitement de la maladie d'alzheimer et d'autres troubles
EA200700909A1 (ru) Азаиндолкарбоксамиды
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire